SUNPHARMA

Sun Pharma’s proposed acquisition of New Jersey-based Organon is set to deliver multiple strategic benefits, including portfolio expansion, stronger engagement with healthcare professionals (HCPs), and a wider global footprint. The USD 12 billion all-cash deal will enhance SUNP’s innovative medicines portfolio by adding a dedicated women’s healthcare segment, strengthen its biosimilars pipeline, and significantly broaden its presence across more than 140 countries, including key markets such as the US, EU, China, Canada, and Brazil. This transaction reinforces SUNP’s global positioning and diversifies its portfolio, with increased exposure to women’s health, innovative therapies, and biosimilars. It also enhances the company’s scale across major international markets. Based on a valuation of approximately 32x 12-month forward earnings.